Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR Therapeutics CRSP is expected to report fourth ... development of two next-generation CAR-T therapy candidates — CTX112 (targeting CD19-positive B-cell malignancies) and CTX131 (targeting ...

CRISPR Therapeutics is the gene-editing specialist ... designation to CRISPR's CTX112, an investigational treatment for certain B-cell malignancies. This designation is reserved for therapies ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... The FDA has designated the company’s CTX112 as a regenerative medicine advanced therapy (RMAT), and ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) saw a large growth in short interest during the month of January.As of January 15th, there was short interest totalling 19,100,000 shares ...

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected ...